Treating Multiple Myeloma Patients with Oral Therapies

Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important.Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide and pomalidomide, the alkylating agents melphalan and cyclophosphamide, the histone deacetylase inhibitor panobinostat, the corticosteroids prednisone and dexamethasone, and the proteasome inhibitor ixazomib.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 6, 2017 Category: Hematology Authors: Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari Tags: Review Article Source Type: research